KRAS and neoplasm: However, after decades of hard work, the acknowledged crucial therapeutic target has been deemed challenging even undruggable for its smooth surface lacking suitable drug-pockets, until the surprising advances have made in the covalent KRAS G12C inhibitors, which specifically trap KRAS G12C bound GDP and restrain tumor growth in patients, for example, AMG510 (sotorasib) has been approved in clinical use.